Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 11 Aug 21 424B4 Prospectus supplement with pricing info
- 10 Aug 21 EFFECT Notice of effectiveness
- 9 Aug 21 S-1/A IPO registration (amended)
- 9 Aug 21 FWP Free writing prospectus
- 9 Aug 21 S-1/A IPO registration (amended)
- 3 Aug 21 S-1/A IPO registration (amended)
-
2 Aug 21 S-1/A IPO registration (amended)
- 16 Jul 21 S-1 IPO registration
ELYM similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-1 of Eliem Therapeutics, Inc. of our report dated May 12, 2021, except for the effects of the reverse stock split discussed in Note 13 to the consolidated financial statements, as to which the date is August 2, 2021, relating to the financial statements of Eliem Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Seattle, Washington
August 2, 2021